References
- Skipper H, Schabel F, Wilcox W. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics ahsociated with curability of experimental leukemia. Cancer Chemother Rep 1964; 35: 1–111
- Early Breast Cancer Trialisis' Collaborative Group T: Syrtemic treatment of early breast cancer by hormonal. cytotoxic, or immune therapy: 133 randoniised trials involving 31,000 recurrences and 24,000 dcaths among 75,000 women. Lancet 1992; 339: 1–15; 71–85
- Rosen PP, Groshen S, Kinrie DW. Prognosis in T2NOMO stage I breast cancer: a 20-year follow-up. J Clin Oncol 1991; 9: 1650–1661
- Rosen P, Groshen W, Saigo P, et al. A long-term follow-up study of survival in stage I (TINoMo) and stage II (TINIMO) hreast carcinoma. J Clin Oncol 1989; 7: 355–366
- Rutqvist LE. Increasing incidence and constant mortality rates of breast cancer: Time trends in Stockholm County 1961-1973. Breast Cancer Res Treat 1984; 4: 233–243
- Rutqvist L, Wallgren A. Long-term survival of 458 young breast cancer patients. Cancer 1985; 55: 658–665
- Rutqvist L, Wallgren A, Nilsson B. Is breast cancer a curable disease?. Cancer 1984; 53: 1793–1800
- Rubens R, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy. Eur J Cancer Clin Oncol 1989; 25: 667–678
- Bhardwaj S, Holland JF, Norton L. An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest 1993; 11: 6–9
- Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231–249
- Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071